iShares Core S&P 500 ETF vs Philip Morris International Inc. — how do they compare? iShares Core S&P 500 ETF trades at $751.54, while Philip Morris International Inc. trades at $190.1 (market cap $300.37B). The key difference: Philip Morris International Inc. pays a 3.05% dividend while iShares Core S&P 500 ETF pays none. Which is the better fit depends on your goals.
| IVV | PM | |
|---|---|---|
Sector | Broad Market / Factor | Consumer Staples |
52-Week High | $763.10 | $192.98 |
52-Week Low | $624.65 | $144.33 |
Market Cap | — | $300.37B |
Enterprise Value | — | $346.86B |
Dividend Yield | — | 3.05% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Philip Morris International (PM) trades at $192.98, up 1.65% today, near the analyst consensus price target of $194. The stock shows a bullish technical trend with strong moving average support. Fundamentally, the company reported robust 2025 results with revenue of $40.65 billion and net income of $11.35 billion, though recent news highlights a $500 million impairment charge and reduced profit guidance for 2026 due to cost pressures.
The outlook remains cautiously optimistic with 68% of analysts rating it a Buy, but investors face headwinds from currency volatility, rising illicit tobacco trade in Europe, and margin compression. The stock's valuation at a P/E of 27.13 appears full priced, requiring continued execution to justify further upside.
Trailing returns across standard periods
Latest headlines on both assets
IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.
Read more on IVV →Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →